DOH Pharmacist Exam key terms

The rate and extent to which the active ingredient or active moiety is absorbed from a dosage form and becomes available at the site of action, usually assessed from plasma concentration versus time data.

The absence of a significant difference in the rate and extent of absorption between two pharmaceutically equivalent products, typically demonstrated by comparative bioavailability studies with confidence interval criteria.

Presystemic metabolism of an orally administered drug in the intestinal wall or liver before it reaches systemic circulation, reducing oral bioavailability relative to intravenous dosing.

The integral of drug plasma concentration over time after a dose, used as a measure of total systemic exposure and a key parameter in bioavailability and bioequivalence assessment.

The time required for the plasma concentration or amount of drug in the body to decrease by half, determined by volume of distribution and clearance for first-order elimination.

The volume of plasma from which a drug is completely removed per unit time, reflecting the combined efficiency of hepatic, renal, and other elimination pathways.

An apparent volume relating the amount of drug in the body to its plasma concentration, indicating the extent of distribution into tissues relative to plasma.

The condition during repeated dosing in which drug input equals drug elimination, so plasma concentrations fluctuate around a constant mean, generally reached after about four to five half-lives.

A pharmacologically inactive derivative that must undergo chemical or enzymatic conversion in the body to release the active drug, often used to improve absorption, stability, or targeting.

The relationship between the chemical structure of a molecule and its biological activity, used to guide modification of functional groups to optimize potency, selectivity, and pharmacokinetic properties.

The spatial arrangement of chemical features in a molecule that is responsible for a specific biological interaction, serving as a template for designing related active compounds.

A chemical group or substituent that can replace another group in a molecule with similar steric and electronic properties while preserving or improving biological activity.

The property of a molecule that is not superimposable on its mirror image, producing enantiomers that may differ markedly in pharmacologic activity, metabolism, and toxicity.

An equimolar mixture of two enantiomers of a chiral compound, which may behave differently from a single purified enantiomer in potency and disposition.

A ligand that binds a receptor and activates it to produce a biological response, having both affinity for the receptor and intrinsic efficacy.

A ligand that binds a receptor with affinity but without intrinsic efficacy, blocking or reducing the effect of agonists; competitive antagonists can be overcome by higher agonist concentrations.

A ligand that binds and activates a receptor but produces a submaximal response even at full receptor occupancy, and can act as a functional antagonist when a full agonist is present.

The maximal biological response a drug can produce when bound to its receptor, distinguishing drugs that can achieve full effect from those with limited intrinsic activity.

The amount of drug required to produce a given effect, reflected in the position of the dose-response curve; a more potent drug achieves the same effect at a lower dose.

A ratio comparing the dose producing toxicity with the dose producing therapeutic effect; a narrow index means small dose changes can cause toxicity or loss of efficacy.

Measurement of drug concentrations in blood, usually for drugs with narrow therapeutic indices, to individualize dosing and maintain concentrations within a target range.

Any noxious and unintended response to a medicine occurring at doses normally used in humans, including type A dose-related and type B idiosyncratic reactions.

A modification of the effect of one drug by another, a food, or an environmental agent, often through altered metabolism, absorption, protein binding, or pharmacodynamic effects.

A clinical situation in which a drug should not be used because the risk of harm outweighs the potential benefit, or because it may worsen an existing condition.

Prescribing or dispensing an approved medicine for an indication, dose, route, or population not covered by its regulatory approval, based on clinical judgment and evidence.

Dispensing a therapeutically equivalent generic product in place of a prescribed brand-name medicine, permitted under pharmacy law where products are judged interchangeable.

A relationship between products containing the same active ingredient in the same amount and dosage form that meet the same compendial or other applicable quality standards.

A designation for products that are pharmaceutically equivalent, bioequivalent, and expected to produce the same clinical effect and safety profile when used as labeled.

A continually updated list of medicines approved for use within a health system, with policies on prescribing, dispensing, and therapeutic interchange to guide cost-effective care.

The study of the costs and outcomes of pharmaceutical products and services, using methods such as cost-effectiveness, cost-benefit, and cost-utility analysis to inform resource allocation.

An economic evaluation comparing the costs and health outcomes of alternative interventions, expressing results as cost per unit of clinical effect such as cost per life-year gained.

A health outcome measure combining length of life with quality of life, where one year in perfect health equals 1.0 and is used in cost-utility analyses.

The study of medicinal substances of natural origin, including their botanical sources, chemical constituents, cultivation, identification, and therapeutic uses.

A naturally occurring nitrogen-containing basic compound found mainly in plants, often pharmacologically active, with examples including morphine, quinine, and atropine.

A plant preparation adjusted so that a specified marker compound or group of compounds falls within a defined concentration range, supporting consistent quality and dosing.

An alteration in the effect of a conventional medicine caused by a botanical product, often through enzyme induction or inhibition, altered transport, or additive pharmacologic effects.

An inactive component of a dosage form added as a diluent, binder, disintegrant, lubricant, preservative, or flavoring to aid manufacture, stability, or patient acceptability.

A formulation designed to release drug gradually over an extended period, reducing dosing frequency and smoothing plasma concentration fluctuations compared with immediate-release products.

Preparation of sterile dosage forms under controlled environmental conditions and validated procedures to prevent microbial and particulate contamination, governed by standards such as USP Chapter 797.

The date after which a compounded preparation must not be used, determined from stability data and assigned based on the formulation, packaging, and storage conditions.

A system of quality assurance requirements ensuring that medicinal products are consistently produced and controlled according to quality standards appropriate to their intended use.

The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem after marketing.

The systematic submission of suspected adverse drug reactions to a regulatory or national monitoring authority, supporting signal detection and post-marketing safety evaluation.

A patient's voluntary agreement to a treatment or procedure after receiving and understanding information about its purpose, risks, benefits, and alternatives.

The ethical and legal obligation of pharmacists to protect patient health information from unauthorized disclosure, except where required or permitted by law.

Any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the healthcare professional, patient, or consumer.

A formal process of obtaining and comparing a patient's complete medication history across transitions of care to identify discrepancies and prevent omissions, duplications, or dosing errors.

The extent to which a patient's medication-taking behavior corresponds with the agreed recommendations of the prescriber, influenced by regimen complexity, cost, and beliefs.

The responsible provision of drug therapy to achieve definite outcomes that improve a patient's quality of life, emphasizing identification and resolution of drug-related problems.

An initial larger dose given to reach therapeutic plasma concentrations rapidly when the time to steady state with maintenance dosing alone would be clinically unacceptable.

Reversible association of drug molecules with plasma proteins such as albumin, which limits the free fraction available to distribute, bind receptors, and undergo elimination.

A graph relating drug dose or concentration to the magnitude of the observed response, used to estimate potency, efficacy, and the steepness of the pharmacologic effect.

A plant-derived chemical compound, such as a flavonoid, terpenoid, or alkaloid, that may contribute to the therapeutic or toxic effects of a botanical product.